GE HealthCare Technologies (GEHC) Company Report

GE HealthCare has submitted 510(k) filings to the FDA for its next-generation SIGNA MRI systems featuring AI-powered workflow platforms to improve exam efficiency and diagnostic precision.
The SIGNA Bolt1 3T offers enhanced clinical efficiency and research capabilities; the SIGNA Sprint with Freelium 1.5T emphasizes sustainability and operational autonomy to broaden MRI access.
Revenue mix: 45% imaging, 26% advanced visualization, 16% patient care, 13% pharmaceutical diagnostics; geographic sales: 46% US, 26% EMEA, 12% China, 17% rest of world, with ~50% recurring revenue.
GE HealthCare has intensified R&D since 2022, showcasing over 40 new technology innovations at RSNA 2025 as part of its strategy to drive precision care.

2 days ago

Morningstar

GE HealthCare submits AI-powered Photon-Counting CT system to FDA

GEHC

Product Launch

GE HealthCare has submitted its Photonova Spectra photon-counting CT system for FDA 510(k) clearance, advancing toward commercialization.
The system uses GE’s proprietary Deep Silicon detector technology to count individual X-ray photons and measure their energy for ultra-high-definition imaging and improved tissue characterization.
Integrated AI algorithms and NVIDIA accelerated computing enable processing of up to 50 times more data than conventional CT, aiming to enhance diagnostic confidence and streamline workflows.
Photonova Spectra supports multiple clinical specialties—including oncology, neurology, musculoskeletal, thoracic, and cardiac imaging—through a universal scan protocol designed to improve efficiency.

8 days ago

Morningstar

GE HealthCare projects mid-single digit growth and 17-20% margins

GEHC

Guidance Update

Product Launch

GE HealthCare reported 6% orders growth, a near-record backlog and a 1.06x book-to-bill in 3Q25, supporting a mid-single digit revenue acceleration in 2026 underpinned by strong order conversion over the next 12 months.
Management reiterated mid-term margin targets of 17–20%, noting 30 bp of ex-tariff expansion in 2025 and expecting a tariff-related earnings tailwind in 2026 after mitigating $260–265 million of tariff costs this year.
The company is launching a wave of next-generation products at RSNA (photon-counting CT, whole-body PET, AVS refreshes, new MRI) that will drive further revenue and margin gains starting in 2027.
Flyrcado partnerships now cover 300,000 images, bolstering confidence in the $500 million by 2028 PDX target as the roll-out scales supply, workflow and reimbursement support.
A new generic Omnipaque entrant covering two small SKUs is expected to have a trivial impact on GE HealthCare’s contrast business and 2026 outlook.
AI adoption is key: over 100 FDA-approved modules, including Air Recon DL on 30% of MRI installs, and the Caption Health ultrasound solution are enhancing product differentiation and pricing power.

Nov 18, 2025, 9:30 AM

Transcript

GE HealthCare outlines growth, margin strategy and innovation

GEHC

Product Launch

Guidance Update

6% trailing orders growth and a near-record backlog (book-to-bill of 1.06×) support acceleration to mid-single-digit revenue growth in 2026.
Targeting 17–20%+ adjusted margins midterm, with ~30 bps expansion in 2025 ex-tariffs and further tariff-related tailwinds in 2026.
Major product pipeline set for RSNA, including photon-counting CT, whole-body PET, next-gen MRI and AVS platforms to drive 2027 revenue.
PDX segment’s Flyrcado has reached ~300,000 images under new partnerships, underpinning a path to $500 M revenue by 2028.
AI-enabled solutions, such as Air Recon DL for MRI and Caption Health in ultrasound, are boosting image quality, throughput and recurring software sales.

Nov 18, 2025, 9:30 AM

Transcript

GE HealthCare outlines growth, margin and product strategy at Jefferies healthcare conference

GEHC

Guidance Update

Product Launch

Revenue Acceleration/Inflection

GE HealthCare delivered 6% Q3 order growth, a near-record backlog and a 1.06x book-to-bill, driven by robust CapEx demand across the U.S., EMEA and China.
The company is targeting mid-single-digit revenue growth over the midterm and anticipates acceleration in 2026, supported by a strong backlog and new product launches at RSNA, with most sales impact translating in late 2026.
Excluding tariffs, GEHC achieved 30 bp margin expansion in 2025 and expects further margin improvement in 2026 as tariff headwinds subside and productivity, pricing and new-product mix leverage gross margin and SG&A.
GEHC reaffirmed its $500 million PDx Flyrcado revenue goal by 2028, having secured partnerships covering 300,000 scans, and remains confident in long-term adoption and payor reimbursement.
The firm has secured 100+ FDA-approved AI modules, notably AIR Recon DL for accelerated, higher-quality MRI and Caption Health in ultrasound, enhancing throughput and recurring software revenue.

Nov 18, 2025, 9:30 AM

Transcript

GE HealthCare expands AI imaging collaboration with DeepHealth

GEHC

New Projects/Investments

GE HealthCare and DeepHealth signed a letter of intent to broaden their U.S. breast cancer screening partnership into a worldwide distribution arrangement, integrating GEHC’s mammography systems with DeepHealth’s Breast Suite and extending into ultrasound AI and remote scanning solutions.
The collaboration will integrate DeepHealth’s AI-powered Thyroid Suite with GE HealthCare’s ultrasound portfolio to automate nodule detection, standardize reporting and reduce exam time by up to 30%, with over 94% of AI-generated reports accepted without correction.
The initiative aims to enhance diagnostic confidence, streamline workflows and expand patient access to expert imaging care globally through advanced AI tools and TechLive™ remote scanning.

Nov 12, 2025, 9:05 PM

Press Release

GE HealthCare raises 2025 profit forecast after Q3 results

GEHC

Earnings

Guidance Update

Demand Weakening

GE HealthCare reported Q3 revenue of $5.14 billion, beating forecasts, and raised its 2025 adjusted EPS guidance to $4.51–$4.63, despite a $265 million profit headwind from new US tariffs.
The Patient Care Solutions segment saw sales down 6%, EBIT down 67%, and margins shrink to 3.7% (from 10.5%) year-on-year.
Overall adjusted EBIT margin contracted by 150 basis points to 14.8%, while adjusted net income fell 6% year-on-year.
Order momentum remained solid with a book-to-bill ratio of 1.06 and organic order intake growth of 6%, driven by US/EMEA demand, though China sales weakened.

Oct 29, 2025, 1:27 PM

Morningstar

GE HealthCare reports Q3 2025 results

GEHC

Earnings

Guidance Update

GE HealthCare delivered $5.1 B in revenue, with 4% organic growth, 6% organic orders growth and a book-to-bill of 1.06x.
Adjusted EBIT was $761 M (14.8% margin, down 150 bps YoY) and adjusted EPS was $1.07, a 6% decline driven by tariff headwinds of $0.16 per share.
Free cash flow totaled $483 M, down $168 M YoY, reflecting higher receivables and tariff payments of approximately $95 M.
The company reaffirmed its 2025 outlook and raised the lower end of adjusted EPS guidance to $4.51–$4.63, while maintaining revenue, margin and free cash flow targets.

Oct 29, 2025, 12:30 PM

Presentation

GE HealthCare reports Q3 2025 results

GEHC

Earnings

Guidance Update

Organic revenue of $5.1 B, up 4% YoY; orders grew 6%; ended with a $21.2 B backlog.
Adjusted EPS of $1.07, down 6% YoY, including a $0.16 tariff headwind; adjusted EBIT margin at 14.8%.
Mitigated ~50% of 2025 gross tariff exposure; on track for a lower net tariff impact in 2026.
Free cash flow of $483 M (99% conversion), down primarily due to higher receivables and tariff payments.
Raised full-year guidance: organic revenue growth ~3%; adjusted EPS $4.51–$4.63; EBIT margin 15.2–15.4%; free cash flow ≥ $1.4 B.

Oct 29, 2025, 12:30 PM

Transcript

GE HealthCare reports Q3 2025 results

GEHC

Earnings

Guidance Update

Share Buyback

In Q3, revenue was $5.1 billion (+4% organic), orders rose 6% and backlog reached $21.2 billion.
Adjusted EPS was $1.07 (-6% y/y), with an adjusted EBIT margin of 14.8% (-150 bps) and $0.16 tariff headwind.
Free cash flow totaled $483 million (99% conversion) and the company repurchased $100 million of shares this quarter.
Full-year 2025 guidance updated: organic revenue growth ~3%, adjusted EPS $4.51–4.63, and >$1.4 billion free cash flow; tariffs expected to impact EPS by $0.45.

Oct 29, 2025, 12:30 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for GE HealthCare Technologies.